Company: PSTV
Filing Date: 2025-06-20
Form Type: S-1/A
Source: 0001193125-25-142935
Chunk: 30

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-20
Form: S-1/A
Chunk 30
---
 condition upon the payment of dividends, whether dividends will be cumulative, and the dates from and after which dividends shall accumulate; |

| • |     | the prices at which, and the terms and conditions on which, the shares of the series may be redeemed, if the 
 shares are redeemable;                                                                                       |

| • |     | the terms and conditions of a sinking or purchase fund for the purchase or redemption of shares of the series, if 
 such a fund is provided;                                                                                          |

| • |     | any preferential amount payable upon shares of the series in the event of the liquidation, dissolution or winding 
 up of, or upon the distribution of any of our assets; and                                                         |

19

| • |     | the prices or rates of conversion or exchange at which, and the terms and conditions on which, the shares of the 
 series may be converted or exchanged into other securities, if the shares are convertible or exchangeable.       |

The particular terms of any additional series of preferred stock, and the transfer agent and registrar for that series, will be described in a prospectus supplement. Any material United States federal income tax consequences and other special considerations with respect to any preferred stock offered under this prospectus will also be described in the applicable prospectus supplement. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to holders of our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock. The issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company, which could depress the market price of our common stock. Series B Preferred Stock Conversion.Each share of Series B Preferred Stock is convertible, at our option or at the option of the holder, at any time, into the number of shares of our common stock determined by dividing the $1,000 stated value per share of the Series B Preferred Stock by a conversion price of $2,547.74 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B Preferred Stock will not have the right to convert any portion of the Series B Preferred Stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion.